Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-27
2006-06-27
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S158100, C424S172100, C424S173100, C530S388230
Reexamination Certificate
active
07067132
ABSTRACT:
Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or γ-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
REFERENCES:
patent: 4853332 (1989-08-01), Mark et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5552303 (1996-09-01), Grabstein et al.
patent: 5574138 (1996-11-01), Grabstein et al.
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 5707616 (1998-01-01), Grabstein et al.
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 5795966 (1998-08-01), Grabstein et al.
patent: 5892001 (1999-04-01), Grabstein et al.
patent: 6165466 (2000-12-01), Granbstein et al.
patent: 6177079 (2001-01-01), Grabstein et al.
patent: 6184359 (2001-02-01), Grabstein et al.
patent: WO96/04306 (1996-02-01), None
Armitage R., et al., “IL-15 Has Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation,”J of Immunology154:483-489,m 1995.
Carson W., et al., “Interleukin (IL) 15 is a Novel Cytokine that Activates Human Natural Killer Cells via Components of the IL-2 Receptor,”J. Exp. Med. 180:1395-1403, 1994.
Collins L., et al., “Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor,”Proc. Natl. Acad. Sci.. USA85:7709-7713, 1988.
Ferrara et al., “Amelioration of Acute Graft VS Host Disease Due to Minor Histocompatibility Antigens by In Vivo Administration of Anti-Interleukin 2 Receptor Antibody,”J. Immunology, 137(6):1874-1877, 1986.
Giri J., et al., “Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15,”The EMBO Journal13:2822-2830, 1994.
Grabstein K., et al., “Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor.”Science264:965-968, 1994.
Harlow et al., “Antibodies: A Laboratory Manual,” published buCold Spring Harbor Laboratories, 285-287.
Harris et al., “Therapeutic antibodies—the coming of age,”Tibtech II:12-44, 1993.
Ju G., et al., “Structure-Function Analysis of Human Interleukin-2,”J. Biol. Chem. 262:5723-5731, 1987.
McMahan C., et al., “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types,”The EMBO Journal10(10):2821-2832, 1991.
Sevier Ed., et al., “Monoclonal Antibodies in Clinical Immunology,”Clinical Chemistry27:1797-1806, 1981.
Tinubu S., et al., “Humanized Antibody Directed to the Il-2 Receptor β-Chain Prolongs Primate Cardiac Allograft Survival,”J. Immunology153:4330-4338, 1994.
Zurawski S., et al., “Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor,”EMBO J. 12(13):5113-5119, 1993.
Grabstein Kenneth H.
Paxton Raymond J.
Pettit Dean K.
Immuner Corp.
Navarro Mark
Tran Paul B.
LandOfFree
Antagonists of interleukin-15 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of interleukin-15, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of interleukin-15 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654282